Oral corticosteroid (OCS)-associated comorbidities/adverse effects by OCS therapy (duration)
| OCS-associated comorbidity/adverse effect | No prescription (n=16 869) | Infrequent short-term treatment (n=3061) | Frequent short-term to long-term treatment >180 days | OCS patients total (n=8524) | ||||
| Total (n=5463) | Frequent short-term (n=934) | Long-term >20 to ≤90 (n=1871) | Long-term >90 to ≤180 (n=1184) | Long-term >180 (n=1474) | ||||
| Eye disorders | 3521 (20.87%) | 693 (22.64%) | 1492 (27.31%) | 219 (23.45%) | 426 (22.77%) | 338 (28.55%) | 509 (34.53%) | 2185 (25.63%) |
| Endocrine disorders | 704 (4.17%) | 121 (3.95%) | 240 (4.39%) | 34 (3.64%) | 72 (3.85%) | 48 (4.05%) | 86 (5.83%) | 361(4.24%) |
| Disorders of the skin and subcutaneous tissue | 421 (2.50%) | 88 (2.87%) | 151 (2.76%) | 28 (3.00%) | 50 (2.67%) | 37 (3.12%) | 36 (2.44%) | 239 (2.80%) |
| Blood and lymphatic disorders | 183 (1.08%) | 30 (0.98%) | 125 (2.29%) | 18 (1.93%) | 36 (1.92%) | 23 (1.94%) | 48 (3.26%) | 155 (1.82%) |
| Gastrointestinal disorders | 315 (1.87%) | 50 (1.63%) | 158 (2.89%) | 25 (2.68%) | 48 (2.57%) | 34 (2.87%) | 51 (3.46%) | 208 (2.44%) |
| Immune system disorders | 2784 (16.50%) | 596 (19.47%) | 934 (17.10%) | 173 (18.52%) | 351 (18.76%) | 193 (16.30%) | 217 (14.72%) | 1530 (17.95%) |
| Nervous system disorders | 322 (1.91%) | 46 (1.50%) | 118 (2.16%) | 8 (0.86%) | 40 (2.14%) | 31 (2.62%) | 39 (2.65%) | 164 (1.92%) |
| Cardiac disorders | 9510 (56.38%) | 1778 (58.09%) | 3687 (67.49%) | 559 (59.85%) | 1205 (64.40%) | 807 (68.16%) | 1116 (75.71%) | 5465 (64.11%) |
| Psychiatric disorders | 4954 (29.37%) | 1030 (33.65%) | 1966 (35.99%) | 307 (32.87%) | 662 (35.38%) | 428 (36.15%) | 569 (38.60%) | 2996 (35.15%) |
| Weakening of the immune defence with increased risk of infection | 455 (2.70%) | 105 (3.43%) | 190 (3.48%) | 25 (2.68%) | 77 (4.12%) | 40 (3.38%) | 48 (3.26%) | 295 (3.46%) |
| Musculoskeletal and connective tissue disorders | 1600 (9.48%) | 328 (1072%) | 1106 (20.25%) | 109 (11.67%) | 266 (14.22%) | 247 (20.86%) | 484 (32.84%) | 1434 (16.82%) |
| Metabolism and nutrition disorders | 6850 (40.61%) | 1229 (40.15%) | 2805 (51.35%) | 407 (43.58%) | 913 (48.80%) | 617 (52.11%) | 868 (58.89%) | 4034 (47.33%) |
| Patients with at least one OCS-associated comorbidity/adverse effect | 13 814 (81.89%) | 2574 (84.09%) | 4929 (90.23%) | 807 (86.40%) | 1654 (88.40%) | 1083 (91.47%) | 1385 (93.96%) | 7503 (88.02%) |
| Number of all OCS-associated comorbidities/adverse effects relative to group size | 1.87 | 1.99 | 2.37 | 2.05 | 2.22 | 2.40 | 2.76 | 2.24 |